ADIS stands for “Early Diagnosis of Alzheimer’s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances”. The research project brings together EU-leading expertise in data science, biotechnology, clinical research as well as public involvement.
As the title already highlights, the partners aim to advance research into one of the most challenging conditions, Alzheimer’s disease. The ADIS project (start: July 2022) ran for three years with a budget of 1.3 million euros.
ADIS will leverage cutting edge science and technology in conjunction with long lasting clinical expertise to provide candidate biomarkers for earlier diagnosis of Alzheimer’s disease. An earlier diagnosis means that treatments slowing down symptom worsening would have higher success chance in the future and that patients could better plan their life. I am very enthusiastic about the motivation and energy of the entire consortium to reach our ambitious goals and really looking forward to the upcoming three years of working together.
Contributing with our experience to research is essential to obtain better results for a better and longer quality of life for people with Alzheimer’s disease and their carers or supporters.
Research does not advance without us and we do not advance without research.
I think it is vital to contribute to research with our lived experience so that we can raise awareness, be part of the solution that may benefit us and others in the future, and fight the stigma around Alzheimer’s disease.
Combining research with the lived experience of people with Alzheimer’s disease is the only way forward to make significant progress from which people who have this disease, or will have it in the future, will benefit.